@entity1209 ( @entity1209 ) is presented in over 30% of @entity5 @entity1 receiving highly/moderately emetogenic chemotherapy (HEC/ @entity17469 ). The currently recommended antiemetic therapy is merely based on the emetogenic level of chemotherapy, regardless of @entity1 's individual risk factors. It is, therefore, critical to develop an approach for personalized management of @entity1209 in the era of precision medicine.A number of variables were involved in the development of @entity1209 . In the present study, we pooled the data from 2 multi-institutional investigations of @entity1209 due to HEC/ @entity17469 treatment in Asian countries. Demographic and clinical variables of 881 @entity1 were prospectively collected as defined previously, and 862 of them had full documentation of variables of interest. The data of 548 @entity1 from Chinese institutions were used to identify variables associated with @entity1209 using multivariate logistic regression model, and then construct a personalized prediction model of nomogram; while the remaining 314 @entity1 out of China (Singapore, South Korea, and Taiwan) entered the external validation set. C-index was used to measure the discrimination ability of the model.The predictors in the final model included sex, age, @entity285 consumption, history of @entity391 pregnancy, history of @entity11535 , body surface area, emetogenicity of chemotherapy, and antiemetic regimens. The C-index was 0.67 (95% CI, 0.62-0.72) for the training set and 0.65 (95% CI, 0.58-0.72) for the validation set. The C-index was higher than that of any single predictor, including the emetogenic level of chemotherapy according to current antiemetic guidelines. Calibration curves showed good agreement between prediction and actual occurrence of @entity1209 .This easy-to-use prediction model was based on chemotherapeutic regimens as well as @entity1 's individual risk factors. The prediction accuracy of @entity1209 occurrence in this nomogram was well validated by an independent data set. It could facilitate the assessment of individual risk, and thus improve the personalized management of @entity1209 .

Personalized Estimate of Chemotherapy-Induced Nausea and XXXX : Development and External Validation of a Nomogram in Cancer @entity1 Receiving Highly/Moderately Emetogenic Chemotherapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity17469 :: ('56477', 'Gene') :: ['MEC'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity11535 :: ('MESH:D009041', 'Disease') :: ['motion sickness'] @entity285 :: ('D000431', 'Chemical') :: ['alcohol'] @entity1209 :: ('MESH:D020250', 'Disease') :: ['CINV', 'Chemotherapy-induced nausea and vomiting']
@entity391 :: (MESH:D014839,Disease) :: ['Vomiting']
